EMA Authorised: Usymro (ustekinumab) — Gedeon Richter Plc.

View source ↗

Summary

EMA authorised Usymro (ustekinumab) by Gedeon Richter for Crohn's disease, psoriasis, and psoriatic arthritis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis

Drugs mentioned

• Usymro (ustekinumab)

Snippet

Status: Authorised. Therapeutic area: Crohn Disease;Psoriasis;Arthritis, Psoriatic. MAH: Gedeon Richter Plc.. Decision date: 09/01/2026